Researchers evaluating the clinical significance of IASLC-proposed criteria found the recommendations better align with clinicopathologic risk factors and improve prognostication. Read more
A multivariate analysis presented by Dr. Andrea Wolf during the World Conference on Lung Cancer shows IASLC models performed well compared to other models. However, there is room for improvement, she said. Read more
IASLC Pathology Committee members say the identification and evaluation of features that result in discordance in measuring invasive tumor size will hopefully improve reproducibility and lead to more accurate tumor staging moving forward. Read more
Pathology—and pathologic staging in particular—can be improved through multidisciplinary efforts. Read more
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more
The UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution. Read more
Lynette M. Sholl, MD, Chief of Thoracic Pathology and Associate Director of the Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School, […] Read more
All information and materials presented on or through IASLC’s websites, or made available or provided by or on behalf of IASLC during any webinar, seminar, or other event or activity, […] Read more
Sponsored by EURACAN and the IASLC, a multidisciplinary group comprised of pathologists, oncologists, surgeons, radiologists, and molecular biologists met July 5 and 6, 2018, to critically review the current histologic […] Read more
The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each […] Read more